All In Biotech

Free tool

FAERS Monitor: Rukobia

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 212950 or its brand name (Rukobia, Fostemsavir Tromethamine). Reports on generic versions are filed under their own applications.

Reports

243

Serious

77

32% of reports

Hospitalization

24

Death reported

19

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use30
  • nausea17
  • death16
  • product dose omission issue15
  • drug ineffective14
  • viral load increased12
  • rash11
  • dizziness10
  • fatigue10
  • pathogen resistance10
  • product residue present9
  • virologic failure9
  • wrong technique in product usage process9
  • diarrhoea8
  • anxiety7

Reports by year received

View as table
YearReports
202010
202128
202246
202352
202438
202546
202623

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,916 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
viral load increasedSignal12268.4154.42,926
virologic failureSignal9145.176.41,146
product residue presentSignal9144.776.21,143
pathogen resistanceSignal1095.151.8839
product dose omission issueSignal154.42.737
wrong technique in product usage processSignal93.82.016
off label useSignal303.02.139
rashSignal112.21.26
anxiety72.11.03
nausea171.91.26
dizziness101.70.92
death161.61.03
fatigue101.10.60
diarrhoea81.10.50
drug ineffective140.90.60

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.